why choose us

First received: October 16, 2022

Clinical Trial: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Gout

Study Type: INTERVENTIONAL


Official Title: A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperu

Brief Summary: The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

Read more